OrsoBio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://orsobio.com
Clinical Trials
4
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
Phase 2
Recruiting
- Conditions
- HypertriglyceridemiaNonalcoholic Fatty Liver Disease
- Interventions
- Drug: PlaceboDrug: TLC-2716 Dose 1Drug: TLC-2716 Dose 2
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- OrsoBio, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT06564584
- Locations
- 🇲🇽
OrsoBio Research Site, Ciudad de México, Mexico
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
Phase 1
Recruiting
- Conditions
- Healthy SubjectsObesityType 2 Diabetes
- Interventions
- Drug: TLC-6740 Oral SolutionDrug: TLC-6740 TabletOther: Placebo Oral SolutionOther: Placebo TabletDrug: Drug Metabolizing Enzyme
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- OrsoBio, Inc
- Target Recruit Count
- 514
- Registration Number
- NCT05822544
- Locations
- 🇳🇿
OrsoBio Reseach Site, Auckland, New Zealand
🇳🇿OrsoBio Research Site, Christchurch, New Zealand
A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance
Phase 2
Active, not recruiting
- Conditions
- Insulin Resistance
- Interventions
- Drug: PlaceboDrug: TLC-3595 Dose 2Drug: TLC-3595 Dose 1
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- OrsoBio, Inc
- Target Recruit Count
- 76
- Registration Number
- NCT05665751
- Locations
- 🇳🇿
OrsoBio Research Site, Christchurch, New Zealand
🇳🇿OrsoBio Reseach Site, Auckland, New Zealand
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- OrsoBio, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT05483998
- Locations
- 🇳🇿
OrsoBio Research Site, Auckland, New Zealand
News
No news found